Puretech Health Plc - Adr (PRTC)

$22.1

-0.4

(-1.78%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $22.10
    $22.15
    $22.10
    downward going graph

    0.0%

    Downside

    Day's Volatility :0.23%

    Upside

    0.23%

    downward going graph
  • $17.08
    $34.00
    $22.10
    downward going graph

    22.71%

    Downside

    52 Weeks Volatility :49.76%

    Upside

    35.0%

    downward going graph

Returns

PeriodPuretech Health Plc - AdrSector (Health Care)Index (Russel 2000)
3 Months
-19.58%
6.4%
0.0%
6 Months
-9.43%
6.0%
0.0%
1 Year
-22.73%
9.6%
0.0%
3 Years
-52.73%
14.8%
-19.4%

Highlights

Market Capitalization
530.1M
Book Value
$1.71
Earnings Per Share (EPS)
-2.4
Wall Street Target Price
57.75
Profit Margin
0.0%
Operating Margin TTM
-38910.0%
Return On Assets TTM
-13.09%
Return On Equity TTM
-13.25%
Revenue TTM
3.3M
Revenue Per Share TTM
0.12
Quarterly Revenue Growth YOY
-97.89999999999999%
Gross Profit TTM
17.4M
EBITDA
-143.2M
Diluted Eps TTM
-2.4
Quarterly Earnings Growth YOY
0.62
EPS Estimate Current Year
-0.5
EPS Estimate Next Year
-0.5
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 6 Wall street analysts offering stock ratings for Puretech Health Plc - Adr(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
5
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 161.31%

Current $22.10
Target $57.75

Company Financials

FY18Y/Y Change
Revenue
16.4M
↑ 2418.62%
Net Income
-43.7M
↓ 241.42%
Net Profit Margin
-266.65%
↓ 5015.73%
FY19Y/Y Change
Revenue
8.7M
↓ 46.93%
Net Income
421.1M
↓ 1064.73%
Net Profit Margin
4.8K%
↑ 5114.07%
FY20Y/Y Change
Revenue
8.3M
↓ 3.99%
Net Income
4.6M
↓ 98.92%
Net Profit Margin
54.77%
↓ 4792.65%
FY21Y/Y Change
Revenue
10.0M
↑ 19.64%
Net Income
-62.7M
↓ 1472.79%
Net Profit Margin
-628.41%
↓ 683.18%
FY22Y/Y Change
Revenue
2.1M
↓ 79.06%
Net Income
-37.1M
↓ 40.9%
Net Profit Margin
-1.8K%
↓ 1144.99%
FY23Y/Y Change
Revenue
3.3M
↑ 59.33%
Net Income
-65.7M
↑ 77.25%
Net Profit Margin
-2.0K%
↓ 199.48%
Q3 FY22Q/Q Change
Revenue
4.3M
↓ 38.93%
Net Income
-11.0M
↓ 61.17%
Net Profit Margin
-256.32%
↑ 146.87%
Q1 FY23Q/Q Change
Revenue
1.6M
-
Net Income
-12.5M
-
Net Profit Margin
-793.78%
-
Q2 FY23Q/Q Change
Revenue
3.2M
↑ 100.0%
Net Income
-25.0M
↑ 100.01%
Net Profit Margin
-793.81%
↓ 0.03%
Q3 FY23Q/Q Change
Revenue
90.0K
↓ 97.14%
Net Income
-20.3M
↓ 18.63%
Net Profit Margin
-22.6K%
↓ 21813.41%
Q1 FY24Q/Q Change
Revenue
178.6K
↑ 98.41%
Net Income
-40.4M
↑ 98.41%
Net Profit Margin
-22.6K%
↑ 0.47%
FY18Y/Y Change
Total Assets
441.8M
↑ 29.99%
Total Liabilities
274.8M
↓ 0.38%
FY19Y/Y Change
Total Assets
941.2M
↑ 113.05%
Total Liabilities
290.8M
↑ 5.82%
FY20Y/Y Change
Total Assets
990.0M
↑ 5.19%
Total Liabilities
336.5M
↑ 15.71%
FY21Y/Y Change
Total Assets
946.0M
↓ 4.44%
Total Liabilities
361.9M
↑ 7.55%
FY22Y/Y Change
Total Assets
702.6M
↓ 25.72%
Total Liabilities
155.1M
↓ 57.15%
FY23Y/Y Change
Total Assets
694.0M
↓ 1.23%
Total Liabilities
125.6M
↓ 19.01%
Q4 FY22Q/Q Change
Total Assets
702.6M
↑ 0.0%
Total Liabilities
155.1M
↑ 0.0%
Q1 FY23Q/Q Change
Total Assets
702.6M
↑ 0.0%
Total Liabilities
155.1M
↑ 0.0%
Q2 FY23Q/Q Change
Total Assets
693.6M
↓ 1.29%
Total Liabilities
184.7M
↑ 19.09%
Q3 FY23Q/Q Change
Total Assets
694.0M
↑ 0.06%
Total Liabilities
235.7M
↑ 27.66%
Q4 FY23Q/Q Change
Total Assets
694.0M
↑ 0.0%
Total Liabilities
235.7M
↑ 0.0%
Q1 FY24Q/Q Change
Total Assets
694.0M
↑ 0.0%
Total Liabilities
125.6M
↓ 46.73%
FY18Y/Y Change
Operating Cash Flow
-72.8M
↓ 17.92%
Investing Cash Flow
-39.6M
↓ 147.38%
Financing Cash Flow
156.9M
↑ 967.55%
FY19Y/Y Change
Operating Cash Flow
-98.2M
↑ 34.84%
Investing Cash Flow
63.7M
↓ 260.57%
Financing Cash Flow
49.9M
↓ 68.19%
FY20Y/Y Change
Operating Cash Flow
-131.8M
↑ 34.3%
Investing Cash Flow
364.5M
↑ 472.55%
Financing Cash Flow
38.9M
↓ 22.12%
FY21Y/Y Change
Operating Cash Flow
-158.3M
↑ 20.06%
Investing Cash Flow
197.4M
↓ 45.85%
Financing Cash Flow
22.7M
↓ 41.53%
Q3 FY22Q/Q Change
Operating Cash Flow
-45.8M
↓ 47.54%
Investing Cash Flow
86.9M
↓ 2625.93%
Financing Cash Flow
-12.1M
↑ 113.26%
Q4 FY22Q/Q Change
Operating Cash Flow
-32.6M
↓ 28.85%
Investing Cash Flow
86.9M
↑ 0.0%
Financing Cash Flow
45.9M
↓ 480.34%
Q1 FY23Q/Q Change
Operating Cash Flow
-32.6M
↑ 0.0%
Investing Cash Flow
86.9M
↑ 0.0%
Financing Cash Flow
45.9M
↑ 0.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-65.1M
↑ 100.0%
Investing Cash Flow
86.9M
↑ 0.0%
Financing Cash Flow
91.9M
↑ 100.0%

Technicals Summary

Sell

Neutral

Buy

Puretech Health Plc - Adr is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Puretech Health Plc - Adr
Puretech Health Plc - Adr
-19.08%
-9.43%
-22.73%
-52.73%
-54.85%
Moderna, Inc.
Moderna, Inc.
-9.87%
21.5%
-2.91%
-60.58%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
1.84%
12.81%
47.11%
81.12%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-6.7%
24.69%
59.95%
200.63%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.28%
11.69%
35.86%
150.1%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Puretech Health Plc - Adr
Puretech Health Plc - Adr
NA
NA
NA
-0.5
-0.13
-0.13
NA
1.71
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Puretech Health Plc - Adr
Puretech Health Plc - Adr
Buy
$530.1M
-54.85%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Insights on Puretech Health Plc - Adr

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 90.0K → 178.56K (in $), with an average increase of 49.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -20.34M → -40.36M (in $), with an average decrease of 98.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 59.9% return, outperforming this stock by 82.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 200.6% return, outperforming this stock by 253.3%

Institutional Holdings

  • Pentwater Capital Management LP

    0.06%
  • Awm Investment Company Inc

    0.03%

Company Information

PureTech Health is a biotechnology company which develops medicines to combat serious diseases.

Organization
Puretech Health Plc - Adr
Employees
90
CEO
Ms. Daphne Zohar
Industry
Health Technology

FAQs